氨氯地平阿托伐他汀钙片治疗老年高血压合并冠心病的临床效果

Clinical Efficacy of Amlodipine-Atorvastatin Calcium Tablets in the Treatment of Elderly Patients with Hypertension Complicated by Coronary Heart Disease

目的 探讨老年高血压合并冠心病(CHD)患者采用氨氯地平阿托伐他汀钙片治疗的临床效果。方法 选取2022年7月至2023年12月商丘市第一人民医院收治的共计80例老年高血压合并CHD患者,以随机数表法分成研究组(n=40)与对照组(n=40),对照组实行氨氯地平治疗,研究组实行氨氯地平阿托伐他汀钙片治疗,比较两组临床疗效、血压水平、心功能、血脂水平及不良反应发生情况。结果 研究组治疗有效率(95.00%)高于对照组(77.50%),差异具有统计学意义(P <0.05);治疗后两组收缩压(SBP)、舒张压(DBP)较治疗前降低,差异具有统计学意义(P <0.05),治疗后研究组SBP、DBP低于对照组,差异具有统计学意义(P <0.05);治疗后两组左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)较治疗前降低,左心室射血分数(LVEF)较治疗前提高,差异具有统计学意义(P <0.05),治疗后研究组LVEDD、LVESD低于对照组,LVEF高于对照组,差异具有统计学意义(P <0.05);治疗后两组低密度脂蛋白胆固醇(LDL-C)、总胆固醇(TC)水平较治疗前降低,高密度脂蛋白胆固醇(HDL-C)水平较治疗前升高,差异具有统计学意义(P <0.05),治疗后研究组LDL-C、TC水平低于对照组,HDL-C水平高于对照组,差异具有统计学意义(P <0.05);研究组不良反应发生率(5.00%)低于对照组(25.00%),差异具有统计学意义(P <0.05)。结论 氨氯地平阿托伐他汀钙片用于老年高血压合并CHD患者的治疗,能够促进临床疗效提升,改善心功能、血脂状况,降低血压水平,安全性较高。

Objective To investigate the clinical efficacy of amlodipine-atorvastatin calcium tablets in the treatment of elderly patients with hypertension complicated by coronary heart disease(CHD).Methods A total of 80 elderly patients with hypertension complicated by CHD treated at The First People's Hospital of Shangqiu from July 2022 to December 2023 were selected.They were randomly divided into a study group(n=40) and a control group(n=40).The control group received treatment with amlodipine,while the study group received treatment with amlodipine-atorvastatin calcium tablets.The clinical efficacy,blood pressure levels,cardiac function,lipid levels,and occurrence of adverse reactions were compared between the two groups.Results The effective rate of treatment in the study group(95.00%) was higher than that in the control group(77.50%),with a statistically significant difference(P < 0.05).After treatment,both systolic blood pressure(SBP) and diastolic blood pressure(DBP) in both groups decreased compared to before treatment,with statistically significant differences(P < 0.05).The SBP and DBP in the study group were lower than those in the control group after treatment,with statistically significant differences(P < 0.05).After treatment,both left ventricular end-diastolic diameter(LVEDD) and left ventricular end-systolic diameter(LVESD) decreased compared to before treatment,and left ventricular ejection fraction(LVEF) increased compared to before treatment,with statistically significant differences(P < 0.05).The LVEDD and LVESD in the study group were lower than those in the control group after treatment,and the LVEF was higher than that in the control group,with statistically significant differences(P < 0.05).After treatment,both low-density lipoprotein cholesterol(LDL-C) and total cholesterol(TC)levels decreased compared to before treatment,and high-density lipoprotein cholesterol(HDL-C) levels increased compared to before treatment,with statistically significant differences(P < 0.05).The LDL-C and TC levels in the study group were lower than those in the control group after treatment,and the HDL-C level was higher than that in the control group,with statistically significant differences(P < 0.05).The incidence of adverse reactions in the study group(5.00%) was lower than that in the control group(25.00%),with a statistically significant difference(P < 0.05).Conclusion Amlodipine-atorvastatin calcium tablets used in the treatment of elderly patients with hypertension complicated by CHD can promote clinical efficacy,improve cardiac function and lipid status,reduce blood pressure levels,and have a higher safety profile.